ReShape Lifesciences (RSLS) said Monday that the US Patent and Trademark Office awarded a notice of allowance for its proprietary diabetes neuromodulation technology, under patent application, titled high-frequency low duty cycle patterns for neural regulation.
The neuromodulation technology uses vagus nerve block technology platform, along with vagus nerve stimulation, to treat type 2 diabetes.
The technology regulates blood glucose through targeted vagal nerve modulation, specifically, blocking and stimulating signals to the liver and pancreas, the company's director of research Jonathan Waataja said.
Once issued, the patent will provide protection until Aug. 4, 2037.
Price: 0.46, Change: +0.15, Percent Change: +48.01
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。